Impact of antidepressant drug adherence on comorbid medication use and resource utilization

Archives of Internal Medicine

Volumn 165, Issue 21, 2005, Pages 2497-2503

  Katon, Wayne ^a   Cantrell, Christopher Ron ^b   Sokol, Michael C ^b   Chiao, Evelyn ^c   Gdovin, Joette M ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United States)

^c XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CITALOPRAM; ESCITALOPRAM; FIBRIC ACID DERIVATIVE; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; SULFONYLUREA; VENLAFAXINE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST CONTROL; DATA BASE; DEPRESSION; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ANTIDEPRESSIVE AGENTS; CORONARY DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG UTILIZATION REVIEW; DYSLIPIDEMIAS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 28344439548     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.21.2497     Document Type: Article

References (36)

1. Kessler RC, Berglund PA, Demler O, et al. The epidemiology of major depressive disorder: results form the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Depression Guideline Panel. Depression in Primary Care: Volume 2: Treatment of Major Depression. Rockville, Md: Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. Report No. 5.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
4. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
5. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care. 1996;2:1239-1246.
6. Revicki DA, Simon GE, Chan K, Katon W, Heiligenstein J. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract. 1998;47:446-452.
7. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
8. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
9. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88-90.
10. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infraction. Arch Intern Med. 2000;160:1818-1823.
11. Evangelista LS, Berg J, Dracup K. Relationship between psychosocial variables and compliance in patients with heart failure. Heart Lung. 2001;30:294-301.
12. Culpepper L. Depression and chronic medical illness: diabetes as a model. Psychiatr Ann. 2004;32:528-534.
13. Lin E, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventative care. Diabetes Care. 2004;27:2154-2160.
14. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes. Arch Intern Med. 2000;160:3278-3285.
15. Sullivan M, Simon G, Spertus J, Russo J. Depression-related costs in heart failure care. Arch Intern Med. 2002;162:1860-1866.
16. Lethbridge-Cejku M, Schiller JS, Bernadel L. Summary health statistics for US adults: National Health Interview Survey, 2002. Vital Health Stat 10. 2004;222:1-151.
17. DAI Study Group. The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study. Diabet Med. 2004;21:738-745.
18. Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med. 1997;102:38-47.
19. National Committee for Quality Assurance (NCQA). Health Plan Employer Data and Information Set (HEDIS). Washington, DC: National Committee for Quality Assurance; 2005.
20. Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
21. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27:2149-2153.
22. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958-2971.
23. Roe CM, Motheral B, Teitelbaum F, Rich MW. Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization. Am J Health Syst Pharm. 2000;57:139-145.
24. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther. 1994;16:316-326.
25. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazapril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324-332.
26. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229-233.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
28. Deyo R, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
29. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol. 2004;57:1040-1048.
30. Melfi CA, Chawla AJ, Crogham TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128-1132.
31. Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotoninreuptake inhibitors. Manag Care Interface. 2003;16:22-27.
32. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288:1403-1409.
33. Katon W, Von Korff M, Ciechanowski P, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27:914-920.
34. Katon W, Schoenbaum M, Fan MY, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry. In press.
35. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3:333-337.
36. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci. 1998;20:73-77.